BE385316A - - Google Patents
Info
- Publication number
- BE385316A BE385316A BE385316DA BE385316A BE 385316 A BE385316 A BE 385316A BE 385316D A BE385316D A BE 385316DA BE 385316 A BE385316 A BE 385316A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- parts
- water
- solutions
- hydrochloride
- Prior art date
Links
- 239000000243 solution Substances 0.000 claims description 27
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 9
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000240 adjuvant Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 claims description 3
- 229960000846 Camphor Drugs 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- -1 alkaloid salts Chemical class 0.000 claims description 3
- 229930013930 alkaloids Natural products 0.000 claims description 3
- 229930007890 camphor Natural products 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 230000003381 solubilizing Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 7
- LBSFSRMTJJPTCW-DSXUQNDKSA-N (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LBSFSRMTJJPTCW-DSXUQNDKSA-N 0.000 description 7
- 229960001811 Quinine Hydrochloride Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 3
- IMUHWLVEEVGMBC-BKUXTCEESA-N (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol;hydron;chloride Chemical compound Cl.C1=CC=C2C([C@@H]([C@@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 IMUHWLVEEVGMBC-BKUXTCEESA-N 0.000 description 2
- VUQMOERHEHTWPE-UHFFFAOYSA-N 1-ethylpiperidin-2-one Chemical compound CCN1CCCCC1=O VUQMOERHEHTWPE-UHFFFAOYSA-N 0.000 description 2
- QVEMWYGBLHQEAK-UHFFFAOYSA-N 2-ethylbutanamide Chemical compound CCC(CC)C(N)=O QVEMWYGBLHQEAK-UHFFFAOYSA-N 0.000 description 2
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 2
- 229960001923 Emetine Hydrochloride Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 229960000278 Theophylline Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- MIMJFNVDBPUTPB-UHFFFAOYSA-N potassium hexacyanoferrate(3-) Chemical compound [K+].[K+].[K+].N#C[Fe-3](C#N)(C#N)(C#N)(C#N)C#N MIMJFNVDBPUTPB-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LJOQGZACKSYWCH-WZBLMQSHSA-N (R)-[(2S,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-WZBLMQSHSA-N 0.000 description 1
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 1H-pyridin-4-one Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- ZFCLAKPTEFRHMA-UHFFFAOYSA-N 2,2,6-trimethylpiperidin-4-one Chemical compound CC1CC(=O)CC(C)(C)N1 ZFCLAKPTEFRHMA-UHFFFAOYSA-N 0.000 description 1
- 229940091110 Antipyrine Drugs 0.000 description 1
- UORJNBVJVRLXMQ-UHFFFAOYSA-N Aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000434299 Cinchona officinalis Species 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N Phenazone Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229960000948 Quinine Drugs 0.000 description 1
- CESKLHVYGRFMFP-UHFFFAOYSA-N Sulfonmethane Chemical compound CCS(=O)(=O)C(C)(C)S(=O)(=O)CC CESKLHVYGRFMFP-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- GPAYXCOQADGNAZ-UHFFFAOYSA-N [2-(methylamino)acetyl] 2-(methylamino)acetate Chemical compound CNCC(=O)OC(=O)CNC GPAYXCOQADGNAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 229940051880 analgesics and antipyretics Pyrazolones Drugs 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 229960003153 aprobarbital Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960004251 hydroquinine Drugs 0.000 description 1
- 230000001622 hypnogenic Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium;1,3,7-trimethylpurine-2,6-dione;benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Description
<Desc/Clms Page number 1>
rocédé pour la préparation de solutions concentrées, stables, utilisables en thérapeutique.
@ On a trouvé qu'il était possible d'utiliser avec avantage les pyridones et les pipéridones comme sol- vant ou comme adjuvant pour la préparation de solutions aqueuses de sels d'alcaloides, de bases puriques, d'hypno- genes, de camphre ou d'autres produits difficilement solubles.
Les pyridones et les pipéridones se distinguent par leur faible toxicité et ne sont pas irritantes. La dose létale de lal-méthyl-2-pyridone en injection sous-cutanée chez la souris est de 2,5 g/kg; la 1-oxyéthyl-2-pyridone(cristaux blancs fondant à 95', obtenus par oxydation du sel quater- naire en solution dans la pyridine et de l'éthylènechlor- hydrine au moyen du ferricyanure de potassium) n'est pas mortelle pour la souris à dose de 5 g/kg par voie intravé- ineuse. Dans quelques cas, les pyridones et les pipéridones
<Desc/Clms Page number 2>
sont employées comme solvants pour la préparation de solu- tions non miscibles à l'eau. Dans d'autres cas, on emploie avec avantage un mélange d'eau aveo la pyridone ou avec de la pipéridone.
Il est connu que les corps tels que l'uré- thane, les alcoylurées, les pyrazolones, les pipérazines, sont des corps utilisés pour rendre solubles dans l'eau, des combinaisons insolubles ou difficilement solubles tel que la quinine et ses sels. Ainsi on a pu déjà préparer des solutions à 50% de chlorhydrate de quinine avec l'aide d'antipyrine et d'uréthane. Ces adjuvants ne sont toutefois pas de corps indifférents, car ils ont des propriétés antipyrétiques et hypnogènes. En utilisant la diéthylacé- tamide, on obtient également des solutions à 50% de chlor- hydrate de quinine. La diéthylacétamide est toutefois beau- coup plus toxique que les pyridones et les pipéridones, et elle est en plus fortement irritante en solution concen- trée.
Le mélange caféine-benzoate de sodium qui est utili- sé selon le brevet suisse no. 145558 pour l'obtention d'une solution à 10% de théophylline, n'est également pas une combinaison thérapeutiquement indifférente. Les pyridones et les pipéridones sont par contre des combinaisons totalement indifférentes et ne produisent aucune irritation. L'anhydride de sarcosine qui constitue également une combinaison indif- férente, permet de préparer des solutions à 40% de chlorhy- drate de quinine, alors qu'avec les pyridones et les pipéri- dones il est possible d'obtenir des solutions de 50 à 70%, qui, par dilution avec de l'eau, ne précipitent pas de sel d' alcaloide.
On n'avait pas prévu l'utilisation des pyri-
<Desc/Clms Page number 3>
dones et de pipéridones, corps très peu toxiques et non irritants comme adjuvants de solvant, parce que p.ex. les pyridones avaient été décrites comme de fortes bases qui fixent à l'acide carbonique de l'air (Journal für Praktische Chemie, 2. Folge, Band 93, p. 363). On pouvait craindre en raison de cette propriété que ces solutions soient fortement irri- tantes. Les solutions aqueuses sont à peu près neutres. Leur pH est situé entre 6,0 et 6,8.
Exemple 1.
En mélangeant 6 parties de chlorhydrate de quinine et 4,9 parties de 1-méthyl-2-pyridone, on obtient 10 parties en volume d'une solution limpide contenant 605 de chlorhydrate de quinine. Si on refroidit celle-ci à 0 C ou si l'on dilue avec de l'eau, il ne se produit aucune précipitation.
Exemple 2.
5 parties de chlorhydrate de quinine et 6 parties de 1--y -dioxypropyl-2-pyridone sont diluées avec de l'eau jusqu'à 25 parties. On obtient une solution lim- pide. Il se forme de la dioxypropylpyridone par oxydation du produit d'addition de la pyridine-monochlorhydrine au moyen d'une solution alcaline de ferricyanure de potassium; il se forme des cristaux blancs, fondant à 113
Exemple 3.
5 parties de 4-pyridone, 4 parties d'eau et 3 parties de chlorhydrate de cinchonine, qui ne se dissolvent qu'en proportion de 5% dans l'eau, sont agitées ensemble. La solution obtenue, qui contient 30% de chlor- hydrate de cinchonine, est limpide et stable.
Exemple 4.
20 parties de chlorhydrate de quinine sont
<Desc/Clms Page number 4>
dissoutes dans 15 parties 1-éthyl-2-pipéridone. On obtient une solution à 66% qu'on peut diluer avec de l'eau à n'im- porte quelle concentration.
Exemple 5.
Une solution à 60% de 2,2,6-triméthyl-4-pi- péridone est portée à une concentration d'eau hydrogène de 6,4 par adjonction d'acide. 8 parties en voulume de la solution ainsi obtenue sont agitées avec 3 parties de chlor- hydrate de dihydroquinine, ce qui permet d'obtenir 10 parties en volume d'une solution neutre à 30% de chlorhydrate d'hy- droquinine. La solution reste limpide, même après dilution aveo de l'eau.
Exemple 6.
Une solution aqueuse à 6% de chlorhydrate d'émétine précipite le sel par refroidissement à 0 C. Si à la place de l'eau, on utilise une solution aqueuse à 21/2% de méthylpipéridone comme solvant, une solution à 7% de chlorhydrate d'émétine reste limpide à 0 o C même lorsqu'on y ajoute un cristal de ce sel.
Exemple 7.
4 parties de théophylline sont dissoutes dans 100 parties d'une solution à 40% de 1-oxyéthyl-2- pyridone. La solution peut être diluée.
Exemple 8.
2,5 parties de camphre sont dissoutes dans 100 parties de 1-méthyl-2-pipéridone. La solution peut être diluée avec de l'eau et est injectable.
Exemple 9.
Une solution à 5% de sulfonal est stable dans l'éthylpipéridone.
<Desc/Clms Page number 5>
Exemple 10.
Une solution à 10% d'acide allylisopropyl- barbiturique est stable dans la 1-méthyl-2-pipéridone. Des solutions plus concentrées peuvent facilement être préparées avec ce solvant, mais lorsqu'on dilue celles-ci avec de l'eau, il se produit une précipitation de l'acide.
<Desc / Clms Page number 1>
rocédé for the preparation of concentrated, stable solutions that can be used in therapy.
@ It has been found that it is possible to use pyridones and piperidones with advantage as a solvent or as an adjuvant for the preparation of aqueous solutions of salts of alkaloids, of purine bases, of hypnogens, of camphor. or other poorly soluble products.
Pyridones and piperidones are distinguished by their low toxicity and are not irritating. The lethal dose of al-methyl-2-pyridone by subcutaneous injection in mice is 2.5 g / kg; 1-oxyethyl-2-pyridone (white crystals melting at 95 ', obtained by oxidation of quaternary salt in solution in pyridine and of ethylenechlorhydrine by means of potassium ferricyanide) is not fatal to mouse at a dose of 5 g / kg by the intravenous route. In some cases, pyridones and piperidones
<Desc / Clms Page number 2>
are used as solvents for the preparation of water-immiscible solutions. In other cases, a mixture of water with pyridone or with piperidone is advantageously employed.
It is known that substances such as urethane, alkyl ureas, pyrazolones, piperazines, are substances used to render insoluble or hardly soluble combinations in water, such as quinine and its salts. Thus it has already been possible to prepare 50% solutions of quinine hydrochloride with the help of antipyrine and urethane. These adjuvants, however, are not indifferent to bodies, as they have antipyretic and hypnogenic properties. By using diethylacetamide, 50% solutions of quinine hydrochloride are also obtained. Diethylacetamide is, however, much more toxic than pyridones and piperidones, and in addition it is strongly irritant in concentrated solution.
The caffeine-sodium benzoate mixture which is used according to Swiss patent no. 145558 for obtaining a 10% solution of theophylline, is also not a therapeutically indifferent combination. Pyridones and piperidones, on the other hand, are completely indifferent combinations and do not produce any irritation. Sarcosine anhydride, which is also an independent combination, makes it possible to prepare 40% solutions of quinine hydrochloride, whereas with pyridones and pipéri- dones it is possible to obtain solutions of 50%. 70%, which, on dilution with water, does not precipitate an alkaloid salt.
The use of pyri-
<Desc / Clms Page number 3>
dones and piperidones, substances which are not very toxic and non-irritating as solvent adjuvants, because for example pyridones had been described as strong bases which bind to carbonic acid in the air (Journal für Praktische Chemie, 2 . Folge, Band 93, p. 363). Because of this property, it was feared that these solutions would be highly irritating. Aqueous solutions are almost neutral. Their pH is between 6.0 and 6.8.
Example 1.
By mixing 6 parts of quinine hydrochloride and 4.9 parts of 1-methyl-2-pyridone, 10 parts by volume of a clear solution containing 605 of quinine hydrochloride are obtained. If this is cooled to 0 C or if it is diluted with water, no precipitation occurs.
Example 2.
5 parts of quinine hydrochloride and 6 parts of 1 - y -dioxypropyl-2-pyridone are diluted with water to 25 parts. A clear solution is obtained. Dioxypropylpyridone is formed by oxidation of the pyridine-monochlorohydrin adduct with an alkaline solution of potassium ferricyanide; white crystals form, melting at 113
Example 3.
5 parts of 4-pyridone, 4 parts of water and 3 parts of cinchonine hydrochloride, which only dissolves in a proportion of 5% in water, are stirred together. The resulting solution, which contains 30% cinchonine hydrochloride, is clear and stable.
Example 4.
20 parts of quinine hydrochloride are
<Desc / Clms Page number 4>
dissolved in 15 parts 1-ethyl-2-piperidone. A 66% solution is obtained which can be diluted with water to any concentration.
Example 5.
A 60% solution of 2,2,6-trimethyl-4-piperidone is brought to a hydrogen water concentration of 6.4 by adding acid. 8 parts by volume of the solution thus obtained are stirred with 3 parts of dihydroquinine hydrochloride, which makes it possible to obtain 10 parts by volume of a 30% neutral solution of hydrochlorine hydrochloride. The solution remains clear even after dilution with water.
Example 6.
A 6% aqueous solution of emetine hydrochloride precipitates the salt by cooling to 0 C. If instead of water, a 21/2% aqueous solution of methylpiperidone is used as solvent, a 7% solution of Emetine hydrochloride remains clear at 0 o C even when a crystal of this salt is added.
Example 7.
4 parts of theophylline are dissolved in 100 parts of a 40% solution of 1-oxyethyl-2-pyridone. The solution can be diluted.
Example 8.
2.5 parts of camphor are dissolved in 100 parts of 1-methyl-2-piperidone. The solution can be diluted with water and is injectable.
Example 9.
A 5% sulfonal solution is stable in ethyl piperidone.
<Desc / Clms Page number 5>
Example 10.
A 10% solution of allylisopropyl barbituric acid is stable in 1-methyl-2-piperidone. More concentrated solutions can easily be prepared with this solvent, but when diluted with water, acid precipitation occurs.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE385316A true BE385316A (en) |
Family
ID=54194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE385316D BE385316A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE385316A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722984A1 (en) * | 1994-07-26 | 1996-02-02 | Effik Laboratoires | Solid drug dispersion in cyclic amide carrier, pref. PVP |
-
0
- BE BE385316D patent/BE385316A/fr unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722984A1 (en) * | 1994-07-26 | 1996-02-02 | Effik Laboratoires | Solid drug dispersion in cyclic amide carrier, pref. PVP |
WO1997004749A1 (en) * | 1994-07-26 | 1997-02-13 | Laboratoires Effik | Method for preparing dry pharmaceutical forms, and resulting pharmaceutical compositions |
EP0761208A1 (en) * | 1994-07-26 | 1997-03-12 | Laboratoires EFFIK | Process for preparing dry pharmaceutical forms and compositions thus made |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0669131B1 (en) | Aquous concentrated solutions containing argatroban | |
CA2102777C (en) | Novel compositions based on taxane class derivatives | |
EP0078785B1 (en) | Salts of valproic acid, their preparation and their use | |
CH630260A5 (en) | ANTIBIOTIC COMPOSITIONS BASED ON A TETRACYCLINE. | |
CA2169747A1 (en) | Water-soluble nimesulide salt, and uses thereof for the treatment of inflammations | |
JPH03849B2 (en) | ||
JPH057371B2 (en) | ||
JP2008502723A (en) | A stabilized composition comprising a therapeutically active agent, citric acid or a conjugate base, and chlorine dioxide | |
LU83423A1 (en) | RADIAL TIRE FOR ALL-TERRAIN VEHICLES | |
JPH02255652A (en) | Benzenesulfonamides and preparation thereof | |
EP0605646B1 (en) | Sparfloxacine salts and solutions containing same | |
BE385316A (en) | ||
EP0099799B1 (en) | Salts of alpha-amino (and imino) acids, omega-sulfonic n-substituted, cationic vectors of high cellular penetration, preparation process | |
CH644015A5 (en) | AQUEOUS INJECTABLE OXYTETRACYCLINE SOLUTION. | |
LU83363A1 (en) | ANTI-TUMOR COMPOSITIONS | |
WO2004030665A1 (en) | Transparent gel composition, for the administration of diclofenac sodium through the skin | |
HU177873B (en) | Further developped process for preparing an aequous solution containing a complex of n-/3-chloro-4-/4-chloro-phenoxy/-phenyl/-2-hydroxy-3,5-diiodo-benzamide with polyvinyl-pyrrolidone | |
EP0599943A1 (en) | Leukotriene receptor antagonist-antihistamine complex | |
CH642378A5 (en) | NEW PARACETAMOL DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE IN THERAPEUTICS. | |
TWI316403B (en) | Glycyrrhizin containing pharmaceutical composition | |
FR2624736A1 (en) | Novel water-dispersible pharmaceutical compositions based on ornidazole | |
US1913323A (en) | Stable concentrated solution for therapeutic purposes | |
EP0092287A2 (en) | Acetylcysteine salts, their preparation and use | |
JP4338517B2 (en) | Salt of guanidine derivative and pharmaceutical preparation comprising the salt | |
FR2535205A1 (en) | Stable aq. solns. of antirheumatics and cobalamin(s) |